Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TELADOC HEALTH, INC.

(TDOC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Canaccord Genuity Adjusts Teladoc PT to $160 From $188, Maintains Buy Rating

11/23/2021 | 10:51am EST


ę MT Newswires 2021
All news about TELADOC HEALTH, INC.
01/19Oppenheimer Adjusts Teladoc's Price Target to $160 From $185, Maintains Outperform Rati..
MT
01/19Berenberg Bank Assumes Coverage on Teladoc With Buy Rating, $141 Price Target
MT
01/18Barclays Adjusts Teladoc's Price Target to $95 From $150, Maintains Equalweight Rating
MT
01/11TRACKINSIGHT : 3 Thematic ETFs with early 2022 allure
TI
01/11Piper Sandler Adjusts Teladoc's Price Target to $118 From $183, Reiterates Overweight R..
MT
01/10TELADOC HEALTH : Investor Presentation - January 2022
PU
01/10TELADOC HEALTH, INC. : Results of Operations and Financial Condition (form 8-K)
AQ
01/10Teladoc Health, Inc. Provides Revenue Guidance for the Year Ending December 31, 2021
CI
01/07Credit Suisse Lowers Teladoc's PT to $151 from $207, Says Investors Concerned with Lack..
MT
01/05Teladoc Health to Participate in J.P. Morgan Healthcare Conference
AQ
More news
Analyst Recommendations on TELADOC HEALTH, INC.
More recommendations
Financials (USD)
Sales 2021 2 030 M - -
Net income 2021 -496 M - -
Net Debt 2021 343 M - -
P/E ratio 2021 -23,5x
Yield 2021 -
Capitalization 12 197 M 12 197 M -
EV / Sales 2021 6,18x
EV / Sales 2022 4,80x
Nbr of Employees 4 026
Free-Float 94,3%
Chart TELADOC HEALTH, INC.
Duration : Period :
Teladoc Health, Inc. Technical Analysis Chart | TDOC | US87918A1051 | MarketScreener
Technical analysis trends TELADOC HEALTH, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Last Close Price 76,19 $
Average target price 147,56 $
Spread / Average Target 93,7%
EPS Revisions
Managers and Directors
Jason N. Gorevic Chief Executive Officer & Director
Mala Murthy Chief Financial Officer
David B. Snow Non-Executive Chairman
Jeff Nadler Chief Information Officer
Lewis Levy Chief Medical Officer
Sector and Competitors